Leptin and obesity

July 26, 2004

PROVIDENCE, R.I. -- For nearly a decade, scientists have known that leptin plays an important fat-burning role in humans. But the map of leptin's path through the body - the key to understanding how and why the hormone works - is still incomplete.

Now a small but critical section of that map is charted, based on new research conducted at Brown Medical School and Rhode Island Hospital and at Harvard Medical School and Beth Israel Deaconess Medical Center.

The research team found that leptin triggers production of the active form of a peptide - áMSH - in the hypothalamus, the small area in the base of the brain that controls hunger and metabolism. Researchers say this peptide, or small protein, is one of the body's most powerful metabolism booster signals, sending a fast, strong message to the brain to burn calories.

This message is then sent to another part of the hypothalamus, where another peptide is produced and released. This stimulates the pituitary gland, which secretes a hormone that relays the message to the thyroid, the master of metabolism. Once activated, the thyroid gland then spreads word to the body's cells to increase energy production.

Research results are published in the online early edition of the Proceedings of the National Academy of Sciences for the week of July 26. The team's contribution to the understanding of leptin function - how áMSH is produced and its power as a metabolic messenger - could help in the search for an obesity treatment, said Eduardo Nillni, an associate professor in the Department of Medicine at Brown Medical School and in Brown's Department of Molecular Biology, Cell Biology and Biochemistry. Nillni is also a senior investigator in the Division of Endocrinology at Rhode Island Hospital.

"If somehow, through a drug, you can increase activity of áMSH, you'd force the body to burn more calories and lose weight," Nillni said. "That would help so many people."

According to the federal Centers for Disease Control and Prevention, 61 percent of adults are overweight or obese and 13 percent of children and adolescents are seriously overweight. This epidemic exacts a steep toll: Each year, about 300,000 Americans die of obesity-related causes. The economic cost of obesity was about $117 billion in 2000, the CDC also reports.

Working with grants from the National Institutes of Health, researchers studied chemical changes in the brains of mice and rats injected with leptin to arrive at their findings.

The Brown/Rhode Island Hospital research team included Nillni and Ronald Stuart. Christian Bjorbaek, Li Guo and Heike Munzberg worked on the project through Harvard and the Beth Is-rael Deaconess Medical Center.
-end-


Brown University

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.